Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 17/20 | 0.83 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023280 | 0.91 | LPAR1 (1.00) | LPAR1LPAR3LPAR2SCN9A | |
| SCHEMBL4023283 | 0.91 | LPAR1 (1.00) | LPAR1LPAR3LPAR2SCN9A | |
| SCHEMBL4020505 | 0.90 | LPAR1 (0.86) | LPAR1LPAR3LPAR2SCN9AENPP2 | |
| SCHEMBL4020507 | 0.90 | LPAR1 (0.86) | LPAR1LPAR3LPAR2SCN9AENPP2 | |
| SCHEMBL4022864 | 0.89 | LPAR1 (1.00) | LPAR1LPAR3LPAR2SCN9AENPP2 | |
| SCHEMBL4023104 | 0.84 | LPAR1 (1.00) | LPAR1LPAR3LPAR2SCN9A | |
| SCHEMBL4022579 | 0.84 | LPAR1 (1.00) | LPAR1LPAR3LPAR2SCN9A | |
| SCHEMBL4027109 | 0.84 | LPAR1 (0.74) | LPAR1LPAR3LPAR2 | |
| SCHEMBL4025255 | 0.83 | LPAR1 (0.86) | LPAR1LPAR3LPAR2SCN9A | |
| SCHEMBL4026337 | 0.83 | LPAR1 (0.86) | LPAR1LPAR3LPAR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115413-A1 | Use of Thiol Compounds to Treat Neurological Disease | ZANKEL, TODD C, MR | 2023-04-13 | — | — | US | disclosed |
| US-20210069129-A1 | Use of Thiol Compounds to Treat Neurological Disease | ZANKEL, TODD C, MR | 2021-03-11 | — | — | US | disclosed |
| US-20190029977-A1 | Use of Thiol Compounds to Treat Neurological Disease | ZANKEL, TODD C, MR | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190029977-A1 | Use of Thiol Compounds to Treat Neurological Disease | TST, NLN, SLC7A11 | LPAR1 3151/4885LPAR3 3043/4885LPAR2 2834/4885 |
| US-20230115413-A1 | Use of Thiol Compounds to Treat Neurological Disease | TST, NLN, SLC7A11 | LPAR1 3151/4885LPAR3 3043/4885LPAR2 2834/4885 |
| US-20210069129-A1 | Use of Thiol Compounds to Treat Neurological Disease | TST, NLN, SLC7A11 | LPAR1 3151/4885LPAR3 3043/4885LPAR2 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.